肿瘤的过继性细胞疗法。
Adoptive T cell therapy of cancer.
机构信息
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
出版信息
Curr Opin Immunol. 2010 Apr;22(2):251-7. doi: 10.1016/j.coi.2010.01.020. Epub 2010 Feb 17.
Abstract
Adoptive transfer of T cells specific for antigens expressed on tumor cells is an attractive strategy for producing targeted and long-lived anti-tumor activity. T cell therapies have shown activity in selected clinical applications but broader application is limited by inadequate persistence of transferred T cells and by tumor-evasion strategies. Current research focuses on defining the optimum type of cell for transfer, genetically modifying infused T cells to augment function and overcome tumor evasion strategies and modulating the host environment.
摘要
过继转输针对肿瘤细胞表面抗原的 T 细胞是产生靶向和长效抗肿瘤活性的一种有吸引力的策略。T 细胞疗法在一些临床应用中显示出活性，但由于转输 T 细胞的持续时间不足和肿瘤逃避策略的限制，其广泛应用受到限制。目前的研究重点是确定最佳的细胞类型进行转输，通过基因修饰输注的 T 细胞来增强功能并克服肿瘤逃避策略，以及调节宿主环境。
相似文献
1
Adoptive T cell therapy of cancer.肿瘤的过继性细胞疗法。
Curr Opin Immunol. 2010 Apr;22(2):251-7. doi: 10.1016/j.coi.2010.01.020. Epub 2010 Feb 17.
2
Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.实体瘤基因工程 T 细胞受体修饰的淋巴细胞的癌症免疫疗法。
Immunol Lett. 2019 Dec;216:51-62. doi: 10.1016/j.imlet.2019.10.002. Epub 2019 Oct 6.
3
Antigen choice in adoptive T-cell therapy of cancer.癌症过继性T细胞治疗中的抗原选择
Curr Opin Immunol. 2009 Apr;21(2):190-9. doi: 10.1016/j.coi.2009.02.006. Epub 2009 Mar 16.
4
Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.嵌合抗原受体T细胞的区域输注以克服实体瘤免疫治疗的障碍
J Vasc Interv Radiol. 2018 Jul;29(7):1017-1021.e1. doi: 10.1016/j.jvir.2018.03.001.
5
Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.采用表达天然 TCR 的抗原特异性 T 细胞的过继免疫疗法。
Cancer Immunol Res. 2019 Apr;7(4):528-533. doi: 10.1158/2326-6066.CIR-18-0888.
6
Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.源自中央记忆细胞而非经肿瘤特异性 TCR 基因修饰的 CD8(+)T 细胞的人类效应 T 细胞，具有用于过继免疫治疗的优越特性。
Cancer Lett. 2013 Oct 10;339(2):195-207. doi: 10.1016/j.canlet.2013.06.009. Epub 2013 Jun 18.
7
Adoptive transfer of virus-specific and tumor-specific T cell immunity.病毒特异性和肿瘤特异性T细胞免疫的过继转移。
Curr Opin Immunol. 2009 Apr;21(2):224-32. doi: 10.1016/j.coi.2009.02.010. Epub 2009 Mar 21.
8
Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.用于癌症过继性免疫治疗的嵌合T细胞：利用所学知识规划未来
Immunotherapy. 2009 Nov;1(6):905-12. doi: 10.2217/imt.09.69.
9
Augmenting engineered T-cell strategies in solid cancers through epigenetic priming.通过表观遗传引发增强实体瘤中工程 T 细胞策略。
Cancer Immunol Immunother. 2020 Nov;69(11):2169-2178. doi: 10.1007/s00262-020-02661-1. Epub 2020 Jul 10.
10
Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?采用高亲和力 TCR 进行过继转移治疗人类实体瘤：如何提高可行性？
Target Oncol. 2012 Mar;7(1):3-14. doi: 10.1007/s11523-012-0207-z. Epub 2012 Feb 15.
引用本文的文献
1
Role of T cells in cancer immunotherapy: Opportunities and challenges.T细胞在癌症免疫治疗中的作用：机遇与挑战。
Cancer Pathog Ther. 2022 Dec 20;1(2):116-126. doi: 10.1016/j.cpt.2022.12.002. eCollection 2023 Apr.
2
Current State of Cell Therapies for Breast Cancer.乳腺癌细胞治疗的现状。
Cancer J. 2022;28(4):301-309. doi: 10.1097/PPO.0000000000000607.
3
Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.免疫疗法的挑战和下一步发展：2018 年和 2020 年美国国立癌症研究所关于实体瘤细胞免疫疗法的研讨会总结。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-003048.
4
Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s.基因修饰 T 细胞治疗骨肉瘤：迈入 21 世纪 20 年代的呼啸时代。
Adv Exp Med Biol. 2020;1257:109-131. doi: 10.1007/978-3-030-43032-0_10.
5
Estimating Residence Times of Lymphocytes in Ovine Lymph Nodes.估计绵羊淋巴结中淋巴细胞的停留时间。
Front Immunol. 2019 Jul 16;10:1492. doi: 10.3389/fimmu.2019.01492. eCollection 2019.
6
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.一种理性设计的全人源 EGFRvIII:CD3 靶向双特异性抗体可将人 T 细胞重定向用于治疗患者来源的脑内恶性胶质瘤。
Clin Cancer Res. 2018 Aug 1;24(15):3611-3631. doi: 10.1158/1078-0432.CCR-17-0126. Epub 2018 Apr 27.
7
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原表达的血液系统恶性肿瘤。
Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
8
Host-Directed Therapeutic Strategies for Tuberculosis.结核病的宿主导向治疗策略
Front Med (Lausanne). 2017 Oct 18;4:171. doi: 10.3389/fmed.2017.00171. eCollection 2017.
9
Large molecular systems landscape uncovers T cell trapping in human skin cancer.大分子系统全景揭示人类皮肤癌中的T细胞滞留现象。
Sci Rep. 2016 Jan 13;6:19012. doi: 10.1038/srep19012.
10
Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice.在小鼠中，单次低剂量阿霉素或紫杉醇预处理增强过继性T细胞转移。
Oncotarget. 2015 Dec 29;6(42):44134-50. doi: 10.18632/oncotarget.6628.
本文引用的文献
1
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).使用透气快速扩增培养器（G-Rex）加速用于临床前和临床应用的抗原特异性 T 细胞的生产。
J Immunother. 2010 Apr;33(3):305-15. doi: 10.1097/CJI.0b013e3181c0c3cb.
2
Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.通过内源性TCR的特异性沉默提高转导的肿瘤特异性TCR在人淋巴细胞中的表达和反应性。
Cancer Res. 2009 Dec 1;69(23):9003-11. doi: 10.1158/0008-5472.CAN-09-1450. Epub 2009 Nov 10.
3
CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help.CD8(+) T 淋巴细胞向病毒感染组织的迁移需要 CD4(+) T 细胞的辅助。
Nature. 2009 Nov 26;462(7272):510-3. doi: 10.1038/nature08511. Epub 2009 Nov 8.
4
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.移植受者中预防或治疗 EBV 相关淋巴增殖性疾病的 EBV 特异性 T 细胞输注的长期结果。
Blood. 2010 Feb 4;115(5):925-35. doi: 10.1182/blood-2009-08-239186. Epub 2009 Oct 30.
5
Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.嵌合抗原受体 T 细胞过继免疫治疗前的抗 B 细胞抗体耗竭有助于清除免疫活性小鼠中的白血病。
Blood. 2009 Dec 24;114(27):5454-63. doi: 10.1182/blood-2009-08-232967. Epub 2009 Oct 30.
6
Engineering lymphocyte subsets: tools, trials and tribulations.工程化淋巴细胞亚群：工具、试验与困境
Nat Rev Immunol. 2009 Oct;9(10):704-16. doi: 10.1038/nri2635.
7
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.一种基于赫赛汀的嵌合抗原受体，其信号结构域经过修饰，可提高转导T淋巴细胞的存活率和抗肿瘤活性。
J Immunol. 2009 Nov 1;183(9):5563-74. doi: 10.4049/jimmunol.0900447.
8
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.源自初始而非中枢记忆性CD8 + T细胞的过继转移效应细胞介导更强的抗肿瘤免疫。
Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74. doi: 10.1073/pnas.0907448106. Epub 2009 Sep 24.
9
Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease.生成对钙调磷酸酶抑制剂有抗性的 EBV 特异性细胞毒性 T 细胞，用于治疗移植后淋巴组织增生性疾病。
Blood. 2009 Nov 26;114(23):4792-803. doi: 10.1182/blood-2009-07-228387. Epub 2009 Sep 21.
10
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506).生成对免疫抑制药物他克莫司（FK506）具有抗性的 Epstein-Barr 病毒特异性细胞毒性 T 淋巴细胞。
Blood. 2009 Nov 26;114(23):4784-91. doi: 10.1182/blood-2009-07-230482. Epub 2009 Sep 16.
Zotero 插件